relugolix + docetaxel

Relugolix + docetaxel is a combination regimen used in the treatment of advanced prostate cancer, particularly in the metastatic or high-risk setting. **Relugolix** is an oral gonadotropin-releasing hormone (GnRH) receptor antagonist that rapidly suppresses testosterone to castrate levels without the testosterone surge associated with GnRH agonists. **Docetaxel** is an intravenous taxane-class cytotoxic chemotherapy agent that inhibits microtubule depolymerization, leading to cell cycle arrest and apoptosis in rapidly dividing cells, including prostate cancer cells. Used in combination, relugolix provides androgen deprivation therapy (ADT), while docetaxel provides cytotoxic antineoplastic effects. This regimen seeks to maximize cancer control via hormonal and cytotoxic mechanisms.

Other names

relugolix plus docetaxelrelugolix and docetaxel